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ABSTRACT: CYP19A1, or aromatase, a cytochrome
P450 responsible for estrogen biosynthesis in humans, is
an important therapeutic target for the treatment of breast
cancer. There is still controversy surrounding the identity
of reaction intermediate that catalyzes carbon−carbon
scission in this key enzyme. Probing the oxy-complexes of
CYP19A1 poised for hydroxylase and lyase chemistries
using resonance Raman spectroscopy and drawing a
comparison with CYP17A1, we have found no signiﬁcant
diﬀerence in the frequencies or isotopic shifts for these two
steps in CYP19A1. Our experiments implicate the
involvement of Compound I in the terminal lyase step
of CYP19A1 catalysis.
The mammalian Cytochrome P450 enzymes participate ina vast array of important physiological functions through
the involvement of potent oxidizing intermediates capable of
epoxidation or hydroxylation of even relatively inert sub-
strates.1−3 Deﬁning the structural dynamics of reactions
involving these enzymatic intermediates, identiﬁed in Figure
1,3 is one of the most challenging and important goals of heme
protein research. While the Compound I species is considered
to be the most common active oxidant, mainly eﬀecting
hydroxylation of substrates,3−5 the ferric peroxo- and hydro-
peroxo- intermediates are also powerful oxidants that have been
suggested to participate in physiologically important pro-
cesses.6,7 The availability of these multiple potential oxidants
leads to various possible outcomes for a given cytochrome P450
under diﬀerent conditions. The peroxo- intermediate formed
upon delivery of an electron to the ferrous-dioxygen adduct can
react in the presence of a susceptible (electrophilic) substrate
or be converted to the subsequent hydroperoxo-form with a
rate depending on the eﬃciency of proton delivery. If delivery
of a second proton to the terminal (distal) oxygen of the
hydroperoxo-intermediate is restricted, O−O bond cleavage is
impeded and the system either “uncouples” by loss of H2O2 or,
if a susceptible substrate such as an alkene is present, a rather
eﬃcient epoxidation reaction can occur.7 In the absence of
conditions which permit interception of these peroxo- and
hydroperoxo- intermediates, Compound I is formed, the
eﬃciency of which also depends on the extent of the
“decoupling” reactions that releases superoxide and hydrogen
peroxide. Based on this abbreviated scheme, it is clear that the
catalytic behavior of a given Cytochrome P450 depends on
numerous factors, including the structure and reactivity of a
particular substrate, the inﬂuence of the partner reductant, and
the environmental conditions.
Aromatase (CYP19A1) plays a crucial role in the biosyn-
thesis of steroid hormones, being responsible for the
conversion of androgens to estrogens.8 The conversion of
androstenedione (AD) to an aromatic C18 estrogen, estrone,
involves two consecutive oxidations at the C19 methyl group
and a third “lyase” step that culminates in cleavage of the C10−
C19 bond of the C19-aldehyde and A ring aromatization
(Figure 2).9,10 The ﬁrst and second oxidative steps are generally
accepted to proceed as classic hydroxylations at the C19 of
androgens mediated by the Compound I species, producing the
C19 primary alcohol, and then, in a second hydroxylation
reaction, a gem-diol intermediate is formed that spontaneously
dehydrates to the C19 aldehyde.9−11 The operative mechanism
associated with the lyase step has been the subject of much
debate during the past two decades.9,12−16 In agreement with
an early proposal by Fishman and Raju,12 Korzekwa et al.
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Figure 1. Catalytic cycle for cytochrome P450.3
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favored involvement of Compound I as the active oxidant.13
However, it has also been suggested that the nucleophilic ferric
peroxo- intermediate attacks the substrate’s aldehyde group
yielding the observed product via decomposition of a transient
peroxo hemiacetal,9 a C−C bond cleavage reaction similar to
that which has been proposed to occur for CYP2B4, CYP51,
and CYP17 in their processing of substrates bearing aldehyde
or ketone functionalities.14−16 However, Hackett et al. applied
density functional theory to a minimal CYP19A1 active site
model, ﬁnding support for an energetic preference for a
Compound I mediated hydrogen abstraction from the C1
carbon of 19-oxo-AD rather than direct attack of the ferric
peroxo-species on the C19 aldehyde carbon.17 Until recently,
deﬁnitive experimental evidence to identify the reactive
intermediates involved in this third stage of the C10−C19
bond cleavage/aromatization process has been lacking.
To address this issue one of our groups recently exploited the
kinetic solvent isotope eﬀect (KSIE) technique, which had
earlier been shown to be useful in quantifying consecutive
proton-transfer processes involved in generating high-valent
iron-oxo intermediates,18 to investigate the bond cleavage
reactions involved in CYP17A1 and CYP19A1 enzymatic
cycles.16,19 Brieﬂy, the eﬀect of deuterium substitution on the
enzymatic rates reveal information regarding the number of
protons involved in O−O bond heterolysis,20 with Compound
I formation, which requires at least 2 protons, leading to
lowered rates in 2H2O, by a factor of ∼1.3, whereas direct
reaction of the nucleophilic ferric peroxo intermediate involves
no proton transfer step. KSIE studies on CYP17A1 showed that
while the hydroxylase reaction, proceeding through a
Compound I intermediate, revealed an expected kH/kD ratio
of 1.3, the stage wherein a C20−C17 lyase reaction occurs
exhibited an inverse KSIE of 0.39, a value consistent with
involvement of a ferric peroxo intermediate.16 In contrast to
this substrate-dependent diﬀerence in mechanism for
CYP17A1, similar KSIE studies for CYP19A1 showed
comparably slower rates in 2H2O vs H2O for conversion of
AD to 19-OH-AD and for conversion of oxo-AD to estrone,
with a KSIE of ≥2.5 in both cases, suggesting the involvement
of the same intermediate during catalysis and therefore
implicating the involvement of Compound I species in the
controversial C10−C19 lyase step for CYP19A1.12,13,17,19
Such KSIE studies suggest the involvement of a Compound I
intermediate in the lyase reaction of CYP19A1. However, a
lingering question to be addressed is what speciﬁc active site
structural element(s), including substrate fragments, enable the
lyase reaction to proceed via the peroxo- intermediate for
CYP17A1/17-OH PREG, but are apparently absent in the case
of CYP19A1 bound with 19-oxo AD, thereby relegating the
task of C−C bond cleavage to the later Compound I
intermediate? Obviously, one potentially important diﬀerence
between the CYP17A1 and CYP19A1 systems is that the
CYP17A1 case houses a substrate bearing a hydroxyl group
juxtaposed to the Fe−O−O fragment, while the relevant
substrate in the CYP19A1 system possesses no such H-bond
donor fragment. However, other potential H-bond donors,
including active site water molecules, are conceivably present to
interact with the Fe−O−O fragment of CYP19A1/AD and
CYP19A1/19-oxo-AD, so the possibility of diﬀerentially
directed H-bonding interactions cannot be ruled out a priori
and prompts further investigation. Gaining insight into this
issue requires a method for direct interrogation of active site
structure. While many spectroscopic methods are available for
documenting structural parameters of the heme, its associated
axial ligands, and its immediate protein environment, resonance
Raman (rR) spectroscopy has been shown to be especially
powerful for these in their stable terminal states as well as for
trapped intermediates.22−25 In fact, in a recent work focused on
the dioxygen adducts of CYP17A1 in the presence of 17-OH-
progesterone (17-OH PROG) or 17-OH-pregnenolone (17-
OH PREG),26 we were able to show that distinctive patterns of
vibrational modes for the Fe−O−O fragments arise for these
two situations. In the case of 17-OH PREG, which shows a 50-
fold increase in its tendency to undergo a lyase reaction,27
compared to 17-OH PROG and proceeding via a peroxo-
intermediate,16 the dioxygen adduct exhibits a vibrational
spectral pattern consistent with H-bonding to the proximal
oxygen atom of the Fe−O−O fragment, an interaction
expected to stabilize a subsequent ferric peroxo-fragment.28
Conversely, the dioxygen adduct of the 17-OH PROG-bound
CYP17A1 system exhibits a vibrational mode pattern associated
with H-bonding to the terminal oxygen in the Fe−O−O
fragment, an arrangement that promotes O−O bond cleavage
and follows the Compound I pathway to eﬀect hydroxylation.29
In the present work rR spectroscopy is used to characterize
the active site structures of dioxygen adducts of CYP19A1
bound with the ﬁrst (AD) or third (19-oxo-AD) substrates
encountered in the enzymatic cycle so as to assess whether or
not there is deﬁnitive evidence for functionally signiﬁcant
structural diﬀerences of the Fe−O−O fragments in the two
cases. As in our earlier works with CYP17A1 and
CYP19A1,16,19,26 the Nanodisc sampling system was used,
which eﬀectively mimics the natural membrane environment,
yielding well-behaved functional properties, as evidenced by the
expected distributions of spin-state populations and enhanced
stability of the dioxygen adducts.30−32
As shown in Figure 3 (trace A), a rather strong feature is
observed at 1130 cm−1 in the rR spectrum of the 16O2 adduct of
CYP19A1 when bound with AD, which is reasonably assigned
to the ν(16O−16O) stretching mode based on the fact that, as
illustrated in the diﬀerence spectrum shown in trace B, it
disappears and is replaced by a new feature located at 1066
cm−1 for the corresponding 18O2 adduct, the 64 cm
−1 shift
being entirely consistent with that expected in the harmonic
oscillator approximation.33 The diﬀerence spectrum shown in
trace C, obtained from solutions prepared from deuterated
solvents, shows a possible, though barely signiﬁcant, shift of the
ν(16O−16O) and ν(18O−18O) modes to slightly higher
frequencies. Shown in the inset are the 16O2−18O2 diﬀerence
Figure 2. Proposed pathway for aromatization reaction of
androstenedione by human CYP19A1.
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spectra acquired in the low frequency region indicating that the
ν(Fe−16O) stretching mode occurs at 538 cm−1, exhibiting an
apparent 16O2−18O2 shift of ∼29 cm−1, a value that is somewhat
higher than that expected in the harmonic oscillator
approximation, which is between 20 and 24 cm−1, depending
on whether the oxygen masses are assumed to be 16 and 18
amu vs 32 and 36 amu.33 Such slightly large shifts observed for
dioxygen adducts of cytochromes P450 have been observed
previously and can be explained in terms of an eﬀective “three
body oscillator” model, (Fe−O−O).34 Shown in Figure 4 are
the corresponding rR spectra obtained for the dioxygen adducts
of CYP19A1 having the third substrate, 19-oxo-AD, bound in
its active site. There it is seen that the observed frequencies and
isotopic shifts obtained are quite similar to the data acquired for
the AD-bound enzyme, with only the values for the ν(Fe−O)
modes diﬀering, but even then only by a few wavenumbers, at
most. It is noted that, while in our experience alteration of
substrate structure within the P450 distal pocket is not
expected to signiﬁcantly aﬀect the ν(Fe−S) mode,35,36 we
nevertheless conﬁrmed that the values of ν(Fe−S) are identical
for CYP19A1 bound with these two substrates (see Supporting
Information), reﬂecting the validity of the point made above.
It is now possible and instructive to compare the vibrational
data for the dioxygen adducts of the CYP17A1 and CYP19A1
systems, bound with various substrates, in light of the
functional properties as reﬂected in the extracted KSIE
data.16,19 In the case of CYP17A1 oxidation of 17-OH-PREG,
the KSIE data support involvement of the peroxo- species and,
as is shown in a recent spectroscopic study,26 the ν(Fe−O)
frequency for this form was observed at 526 cm−1, which signals
an H-bonding interaction with the proximal O-atom of the Fe−
O−O fragment, whereas the ν(Fe−O) mode for the dioxygen
adduct of 17-OH PROG, as well as the data for dioxygen
adducts of PROG and PREG, which undergo hydroxylation
reactions, appear near 540 cm−1 and are consistent with H-
bond donation to the terminal oxygen of the Fe−O−O
fragment.24,25,37−40 The essential point is that the internal
modes of Fe−O−O fragments, especially the ν(Fe−O) modes,
diﬀer considerably for systems poised for the lyase and
hydroxylase reaction pathways. Consequently, the quite similar
vibrational mode patterns observed here for dioxygen adducts
with the ﬁrst and third substrates of CYP19A1 are consistent
with the similar KSIE values obtained for the associated
reactions and provide convincing evidence for an H-bonding
interaction with the terminal oxygen atom of the Fe−O−O
fragment that would facilitate O−O bond cleavage and imply
the involvement of Compound I.
Returning to the question posed above regarding functionally
important active site structural elements, the collection of rR
data acquired for the dioxygen adducts of CYP19A1 with two
diﬀerent substrates and, previously for CYP17A1 with four
diﬀerent substrates,26 provides evidence indicating that
CYP17A1 housing the “lyase promoting substrate”, 17-OH
PREG, represents a special case in which the substrate hydroxyl
group is uniquely positioned to provide an H-bonding
interaction with the proximal oxygen atom of the Fe−O−O
fragment, an active site structural arrangement that is not
duplicated even with the structurally very similar 17-OH
PROG,26 conﬁrming the importance of a ﬁnely tuned active site
architecture in orchestrating the enzymatic cycles of these
enzymes. The spectroscopic data acquired here for oxy-
CYP19A1 bound with AD and 19-oxo-AD suggest that neither
of these systems gives rise to the unusual H-bonding interaction
with the proximal oxygen of the Fe−O−O fragment. Instead
they exhibit a vibrational spectral pattern consistent with H-
bond donation to the terminal oxygen and therefore implicate
Compound I in both hydroxylation and aromatization steps of
Figure 3. High frequency rR spectra of AD-bound oxy CYP19A1 (A)
and the diﬀerence traces, 16O2−18O2 in H2O buﬀer (B) and 16O2−18O2
in D2O buﬀer (C). Inset shows corresponding diﬀerence traces in low
frequency region.
Figure 4. High frequency rR spectra of 19-oxo-AD-bound oxy
CYP19A1 (A) and the diﬀerence traces, 16O2−18O2 in H2O buﬀer (B)
and 16O2−18O2 in D2O buﬀer (C). Inset shows corresponding
diﬀerence traces in low frequency region.
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CYP19A1 catalysis. Finally, it is interesting consider the
necessity for divergent mechanisms operating in C−C bond
cleavage in terms of the demands imposed by the substrate
structure. The lyase reaction proceeds through a more
commonly encountered Compound I pathway for CYP19A1
via attack on the susceptible C1−H bond. Inasmuch as no such
reaction is possible with the lyase substrates of CYP17A1, the
system has evolved a “substrate-assisted” catalysis, facilitating
the cleavage by employing a ferric peroxo- intermediate
stabilized by H-bonding from the substrate hydroxyl fragment.
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